PharmaGraphX

Log in Get Started

Rufinamide

Banzel

Biologic agent

Standard

Half-life

6-10 hours

Protein Binding

34%

Metabolized By

N/A

External

Drugs.com

Clinical alerts

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

CNS depressant

Additive sedation with other CNS depressants and alcohol

Mechanism of action

Modulates sodium channel activity; used for Lennox-Gastaut syndrome

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Epilepsy
·Lennox Gastaut Syndrome
·Healthy Subjects
·Lennox-Gastaut Syndrome
·Refractory Partial Seizures

Interactions

No curated interaction pairs are recorded for Rufinamide. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Headache
Dizziness
Fatigue
Somnolence

Food, alcohol & herbal

Food

Take with food

Alcohol · moderate

Additive CNS depression

Pharmacokinetics

Half-life: 6-10 hours
Protein binding: 34%
Induces: CYP3A4

Pregnancy & lactation

Not recorded for Rufinamide. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement